Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Present and Future of Prostate Cancer Urine Biomarkers

  • Rigau, Marina|||0000-0002-1691-454X
  • Olivan, Mireia|||0000-0002-8464-0827
  • García, Marta|||0000-0001-5155-4730
  • Sequeiros, Tamara|||0000-0002-0908-2263
  • Montes, Melania|||0000-0002-4268-6608
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Llauradó i Miravall, Marta
  • Planas Morin, Jacques|||0000-0002-0222-584X
  • de Torres, Inés|||0000-0002-5495-9140
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Cooper, Colin
  • Reventós, Jaume
  • Clark, Jeremy
  • Doll, Andreas|||0000-0001-8965-8682
In order to successfully cure patients with prostate cancer (PCa), it is important to detect the disease at an early stage. The existing clinical biomarkers for PCa are not ideal, since they cannot specifically differentiate between those patients who should be treated immediately and those who should avoid over-treatment. Current screening techniques lack specificity, and a decisive diagnosis of PCa is based on prostate biopsy. Although PCa screening is widely utilized nowadays, two thirds of the biopsies performed are still unnecessary. Thus the discovery of non-invasive PCa biomarkers remains urgent. In recent years, the utilization of urine has emerged as an attractive option for the non-invasive detection of PCa. Moreover, a great improvement in high-throughput "omic" techniques has presented considerable opportunities for the identification of new biomarkers. Herein, we will review the most significant urine biomarkers described in recent years, as well as some future prospects in that field.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer

  • Sequeiros, Tamara|||0000-0002-0908-2263
  • Rigau, Marina|||0000-0002-1691-454X
  • Chiva, Cristina
  • Montes, Melania|||0000-0002-4268-6608
  • Garcia-Grau, Iolanda
  • García, Marta|||0000-0001-5155-4730
  • Diaz-Mercedes, Sherley|||0000-0002-8164-8639
  • Celma, Ana|||0000-0002-3128-3811
  • Bijnsdorp, Irene
  • Campos, Alexandre
  • Di Mauro, Primiano
  • Borrós, Salvador|||0000-0002-4003-0381
  • Reventós, Jaume
  • Doll, Andreas|||0000-0001-8965-8682
  • Paciucci, Rosanna|||0000-0001-5651-5933
  • Pegtel, Michiel
  • de Torres, Inés|||0000-0002-5495-9140
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Olivan, Mireia|||0000-0002-8464-0827
Rapid and reliable diagnosis of prostate cancer (PCa) is highly desirable as current used methods lack specificity. In addition, identification of PCa biomarkers that can classify patients into high- and low-risk groups for disease progression at early stage will improve treatment decision-making. Here, we describe a set of protein-combination panels in urinary extracellular vesicles (EVs), defined by targeted proteomics and immunoblotting techniques that improve early non-invasive detection and stratification of PCa patients.We report a two-protein combination in urinary EVs that classifies benign and PCa patients (ADSV-TGM4), and a combination of five proteins able to significantly distinguish between high- and low-grade PCa patients (CD63-GLPK5-SPHM-PSA-PAPP). Proteins composing the panels were validated by immunohistochemistry assays in tissue microarrays (TMAs) confirming a strong link between the urinary EVs proteome and alterations in PCa tissues. Moreover, ADSV and TGM4 abundance yielded a high diagnostic potential in tissue and promising TGM4 prognostic power. These results suggest that the proteins identified in urinary EVs distinguishing high- and low grade PCa are a reflection of histological changes that may be a consequence of their functional involvement in PCa development. In conclusion, our study resulted in the identification of protein-combination panels present in urinary EVs that exhibit high sensitivity and specificity for PCa detection and patient stratification. Moreover, our study highlights the potential of targeted proteomic approaches-such as selected reaction monitoring (SRM)-as diagnostic assay for liquid biopsies via urinary EVs to improve diagnosis and prognosis of suspected PCa patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Molecular Markers for Prostate Cancer in Formalin-Fixed Paraffin-Embedded Tissues

  • Sequeiros, Tamara|||0000-0002-0908-2263
  • García, Marta|||0000-0001-5155-4730
  • Montes, Melania|||0000-0002-4268-6608
  • Olivan, Mireia|||0000-0002-8464-0827
  • Rigau, Marina|||0000-0002-1691-454X
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • de Torres, Inés|||0000-0002-5495-9140
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Reventós Puigjaner, Jaume|||0000-0002-2154-6593
  • Doll, Andreas|||0000-0001-8965-8682
Prostate cancer (PCa) is the most frequently diagnosed type of cancer in developed countries. The decisive method of diagnosis is based on the results of biopsies, morphologically evaluated to determine the presence or absence of cancer. Although this approach leads to a confident diagnosis in most cases, it can be improved by using the molecular markers present in the tissue. Both miRNAs and proteins are considered excellent candidates for biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues, due to their stability over long periods of time. In the last few years, a concerted effort has been made to develop the necessary tools for their reliable measurement in these types of samples. Furthermore, the use of these kinds of markers may also help in establishing tumor grade and aggressiveness, as well as predicting the possible outcomes in each particular case for the different treatments available. This would aid clinicians in the decision-making process. In this review, we attempt to summarize and discuss the potential use of microRNA and protein profiles in FFPE tissue samples as markers to better predict PCa diagnosis, progression, and response to therapy.